Literature DB >> 32319565

miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.

Ke-Jing Zhang1, Yu Hu1, Na Luo1, Xin Li1, Fei-Yu Chen1, Jia-Qi Yuan1, Lei Guo1.   

Abstract

Triple‑negative breast cancer (TNBC) is a subtype of breast cancer with a high degree of malignancy. TNBC is prone to distant metastasis and has a poor prognosis. A number of TNBC‑related microRNAs (miRNAs) have been studied and identified. However, the detailed roles of miR‑574‑5p in TNBC remain poorly understood. miR‑574‑5p, SRY (sex determining region Y)‑box 2 (SOX2), B‑cell lymphoma/leukaemia 11A (BCL11A), SKI like proto‑oncogene (SKIL) and epithelial‑mesenchymal transition (EMT)‑related miRNAs and proteins were measured by reverse transcription‑quantitative PCR and western blotting analysis, respectively. A luciferase reporter assay was employed to validate the direct targeting of SOX2 and BCL11A by miR‑574‑5p. MTT, colony formation and Transwell assays were performed to analyse the biological functions of miR‑574‑5p in TNBC cells. A nude mouse xenograft model was used to verify the effects of miR‑574‑5p on the tumorigenesis of TNBC in vivo. The results demonstrated that miR‑574‑5p levels were decreased in breast cancer tissues and cells. miR‑574‑5p repressed proliferation, migration and EMT in TNBC cells. Further experiments confirmed that miR‑574‑5p reduced tumour size and metastasis in vivo. miR‑574‑5p targeted BCL11A and SOX2 to inhibit the SKIL/transcriptional co‑activator with PDZ‑binding motif/connective tissue growth factor axis, and the inhibitory effect of miR‑574‑5p in TNBC cells was at least partly dependent on SOX2 and BCL11A. In addition, the regulation of downstream oncogenes by SOX2 was dependent on BCL11A. To the best of our knowledge, this is the first study to report the association between the miR‑574‑5p/BCL11A/SOX2 axis and the tumorigenesis of TNBC, which provides a new mechanism for understanding the progression of TNBC.

Entities:  

Year:  2020        PMID: 32319565     DOI: 10.3892/ijo.2020.4995

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

Review 1.  The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.

Authors:  Ioanna Akrida; Vasiliki Bravou; Helen Papadaki
Journal:  Mol Biol Rep       Date:  2022-05-23       Impact factor: 2.742

Review 2.  The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

Authors:  Utpalendu Paul; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-03-02       Impact factor: 2.742

3.  Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis.

Authors:  Wei Peng; Jian-Di Li; Jing-Jing Zeng; Xiao-Ping Zou; Deng Tang; Wei Tang; Min-Hua Rong; Ying Li; Wen-Bin Dai; Zhong-Qing Tang; Zhen-Bo Feng; Gang Chen
Journal:  Cancer Cell Int       Date:  2020-08-14       Impact factor: 5.722

4.  Long non-coding RNA MIR100HG promotes the migration, invasion and proliferation of triple-negative breast cancer cells by targeting the miR-5590-3p/OTX1 axis.

Authors:  Fei-Yu Chen; Zhi-Yang Zhou; Ke-Jing Zhang; Jian Pang; Shou-Man Wang
Journal:  Cancer Cell Int       Date:  2020-10-16       Impact factor: 5.722

5.  hsa_circ_0008234 inhibits the progression of lung adenocarcinoma by sponging miR-574-5p.

Authors:  Wei Jiang; Yaozhou He; Zijian Ma; Yu Zhang; Chengpeng Zhang; Nianpeng Zheng; Xing Tang
Journal:  Cell Death Discov       Date:  2021-05-28

6.  The Search of miRNA Related to Invasive Growth of Nonfunctioning Gonadotropic Pituitary Tumors.

Authors:  Joanna Boresowicz; Paulina Kober; Natalia Rusetska; Maria Maksymowicz; Agnieszka Paziewska; Michalina Dąbrowska; Natalia Zeber-Lubecka; Jacek Kunicki; Wiesław Bonicki; Jerzy Ostrowski; Janusz A Siedlecki; Mateusz Bujko
Journal:  Int J Endocrinol       Date:  2020-12-05       Impact factor: 3.257

Review 7.  Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Authors:  Qinqin Li; Zhenghuan Rao; Yanlin Wang; Lei Zhang; Jing Chen; Runlan Wan; Alexander Tobias Teichmann
Journal:  Cancer Cell Int       Date:  2021-06-10       Impact factor: 5.722

8.  SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling.

Authors:  Tai-Yu Chen; Ji Zhou; Peng-Cheng Li; Chun-Han Tang; Ke Xu; Tao Li; Tao Ren
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.